8th International Conference on Malignancies in AIDS and Other Immunodeficiencies
April 29-30, 2004
Main Auditorium, Natcher Conference Center
National Institutes of Health Campus, Bethesda, Maryland
Presented by the National Cancer Institute

Program

Thursday, April 29

8:00 AM – 6:00 PM Poster Presentations

8:30 AM Opening Remarks and Welcome
Jodi B. Black, Ph.D., Program Director, AIDS Malignancy Program, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH)

8:40 AM - 9:55 AM Plenary Lectures
Moderator: Jodi B. Black, Ph.D., Program Director, AIDS Malignancy Program, DCTD, NCI, NIH

8:40 S1 Phase I Study of Interleukin-2 and Stem Cell Factor in Patients with AIDS or HIV and Cancer
Michael Caligiuri, M.D., Director, Ohio State University Comprehensive Cancer Center

9:05 S2 NIH HIV Vaccine Initiatives
Richard Koup, M.D., Senior Investigator and Chief, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH

9:30 S3 Immune Response to Viruses
Louis Picker, M.D., Associate Director, Vaccine and Gene Therapy Institute, Director of the Vaccine Program, and Director, Pathobiology and Immunology Division, Oregon Health and Sciences University (OHSU)

9:55 AM Break

10:25 AM - 12:20 PM Human Papillomavirus (HPV) Immunology
Moderators: Joel Palefsky, F.R.C.P.(C), Director, Clinical Research Center, University of California, San Francisco (UCSF)
T-C Wu, M.D., Ph.D., Associate Professor of Pathology, Oncology, Obstetrics and Gynecology and Molecular Microbiology and Immunology, The Johns Hopkins University (JHU)

10:25 S4 HPV Infection in the Context of Highly Active Antiretroviral Therapy (HAART)
Joel Palefsky, M.D., F.R.C.P.(C), Director, Clinical Research Center, UCSF

10:45 S5 Development of HPV Human T Cell Mediated Assays
Chien-Fu Hung, Ph.D., Assistant Professor of Pathology, JHU

11:05 S6 Overview and Challenges to Assessing T Cell Responses to HPV
Malcolm John, M.D., M.P.H., Assistant Clinical Professor and Director, PositiveHealth Practice, UCSF
11:25  S7  Advances in the Immunology of HPV and the Continued Need for a Therapeutic HPV Vaccine
Martin Kast, Ph.D., Walter A. Richter Chair for Cancer Research, Norris Comprehensive Cancer Center, University of Southern California (USC)

11:40  S8  Investigational HPV (Types 6, 11, 16, 18) L1 VLP Vaccine - Development Update
Eliav Barr, M.D., Senior Director, Biologics Clinical Research, Merck Research Laboratories

Noon  S9  Update on the Development of an HPV-16/18 Prophylactic Cervical Cancer Vaccine
Gary Dubin, M.D., Vice President, Worldwide STD Vaccine Development, Programs and Adult Vaccine Franchise, GlaxoSmithKline Biologicals

12:20 PM  Lunch

1:30 - 2:30 PM  Abstract Presentations
Moderator: Doug Lowy, M.D., Laboratory Chief, Laboratory of Cellular Oncology, Center for Cancer Research (CCR), NCI, NIH

1:30  1,2  Cancer Incidence and Survival Times Among Adults with AIDS in the Pre-HAART and HAART Eras
Nancy Hessol, M.S.P.H., Assistant Adjunct Professor, UCSF

1:45  3  Assessment of HPV DNA Testing as an Adjunct to Primary Cervical Cytologic Screening in HIV+ Women
Tiffany Harris, Ph.D., Instructor, Department of Epidemiology and Population Health, Albert Einstein College of Medicine

2:00  4  Artemisinin Is Cytotoxic for HPV-expressing Cervical Epithelial Cells but Not Primary Cervical Cells
Astrid Baege, M.D., Research Fellow, CCR, NCI, NIH

2:15  5  A Novel Therapy for Cervical Cancer Using Spliceosome-mediated RNA Trans-splicing
Michael Patrick, B.S., Graduate Student, CCR, NCI, NIH

2:30 PM  Break

3:00- 4:00 PM  Immunology and Oncogenesis
Moderator: Cliona Rooney, Ph.D., Professor, Baylor College of Medicine

3:00  S10  Activation of CD21 and CD23 Gene Expression by Kaposi’s Sarcoma Herpesvirus (KSHV) Replication and Transcription Activator (RTA)
Jae Jung, Ph.D., Professor of Microbiology and Molecular Genetics, Harvard Medical School

3:20  S11  Downregulation of MHC-I Molecules by Virally-encoded E3-ubiquitin Ligases
Laurent Coscoy, Ph.D., Assistant Professor of Immunology, University of California, Berkeley

3:40  S12  Improving Survival, Expansion and Persistence of Adoptively-transferred Tumor-specific CTLs
Cliona Rooney, Ph.D., Professor, Baylor College of Medicine

4:00 - 5:00 PM  Abstract Presentations
Moderator: Joseph Pagano, M.D., Professor of Medicine, University of North Carolina

4:00  6  The Mutator Pathway is a Feature of Immunodeficiency-related Lymphomas
Alex Duval, M.D., Ph.D., INSERM Institute

4:15  7  Expression of Activation Induced Cytidine Deaminase, Germinal Center B Cell Gene, Is Induced by Infection with Epstein-Barr Virus (EBV)
Marta Epeldegui, Ph.D. Candidate, University of California, Los Angeles
4:30  8  EBV Infection of NOD/SCID Mice Reconstituted with Human Hematopoietic CD34+ Cells
Miguel Islas-Ohlmayer, M.D., Post-doctoral Researcher, University of Texas Southwestern
Medical Center

4:45  9  RRV-associated Malignancies in the SIV-infected Rhesus Macaque
Scott W. Wong, Ph.D., Associate Scientist, OHSU

5:00 PM  Adjourn to posters

Friday, April 30

8:00 AM - Poster Presentations
6:00 PM

8:30 AM  Introductory Remarks
Ellen G. Feigal, M.D., Vice President of Clinical Sciences and Deputy Scientific Director,
Translational Genomics Research Institute (TGen)

8:40 - 9:35 AM  Plenary Lectures
Moderators: Ellen G. Feigal, M.D., Vice President of Clinical Sciences and Deputy Scientific Director,
Translational Genomics Research Institute (TGen)
Michael Marco, International Program Coordinator, Adult AIDS Clinical Trials Group,
Social and Scientific Systems

8:40  S13  Survey of Research in AIDS-Kaposi’s Sarcoma (KS) in Zimbabwe
Margaret Borok, M.D., Senior Lecturer, University of Zimbabwe College of Health Sciences

9:10  S14  Cervical Cancer Prevention - A Paradigm Shift?
Lynette Denny, M.B., Ch.B., M.M.E.D., Ph.D., F.C.O.G. (SA), Associate Professor and Senior
Specialist, University of Cape Town, South Africa

9:35 - 10:35 AM  Clinical Session: Bone Marrow Transplantation for AIDS-related Lymphoma
Moderators: David T. Scadden, M.D., Director, Hematologic Malignancies and Experimental
Hematology and Co-Director, AIDS Research Center, Massachusetts General Hospital and
Harvard Medical School
Lawrence Kaplan, Clinical Professor of Medicine, UCSF and Program Member, UCSF
Comprehensive Cancer Center

9:35  S15  Autologous Stem Cell Transplantation for AIDS-related Lymphoma: AIDS Malignancy
Consortium 020
David T. Scadden, M.D., Director, Hematologic Malignancies and Experimental Hematology and
Co-Director, AIDS Research Center, Massachusetts General Hospital and Harvard Medical School

9:45  S16  Long Term Remission with Autologous Stem Cell Transplantation in High Risk HIV Associated
Lymphoma
Amrita Y. Krishnan, M.D., Staff Physician, City of Hope Comprehensive Cancer Center

10:00  S17  High-dose Therapy Plus Autologous Hematopoietic Stem Cell Transplantation for HIV-related
Lymphoma: Results and Impact on HIV Disease
Jean Gabarre, M.D., Hôpital Pitié-Salpêtrière, France

10:15  10,11  Clinical Outcome and Immunoreconstitution in HIV-related Lymphomas After High Dose
Therapy and Peripheral Blood Stem Transplantation
Cecilia Simonelli, M.D., Division of Medical Oncology A, National Cancer Institute, Aviano,
Italy

10:25  Discussion
10:35 AM Break

11:00 AM - Abstract Presentations
Moderators: Elliott Kieff, M.D, Ph.D., Harriett Ryan Albee Professor of Microbiology and Molecular Genetics, Co-Director, Channing Laboratory, Harvard Medical School, and Senior Physician, Brigham and Women’s Hospital
Alexandra M. Levine, M.D., Distinguished Professor of Medicine, Chief of Hematology, and Ronald H. Bloom Family Chair in Lymphoma, USC School of Medicine and Medical Director, Norris Cancer Hospital and Research Institute

11:00 12 Treatment of SCID Mice with a Statin Inhibits the Development of EBV-associated Lymphoma
Jeffrey Cohen, M.D., Jeffrey Cohen, M.D., Head of Medical Virology Section, Laboratory of Clinical Infectious Diseases, NIAID, NIH

11:15 13 Antiviral Targeting of NF-κB and EBV Viral Latency in Burkitt Lymphoma
William Harrington, Jr., M.D., Assistant Professor of Hematology/Oncology, University of Miami School of Medicine

11:30 14 Liposome Encapsulated Doxorubicin (TLC D-99, Myocet™) with Cytoxan, Vincristine and Prednisone for AIDS-related Lymphoma: Therapy Results and Correlates of Response
Anil Tulpule, M.D., Assistant Professor of Medicine, USC and Norris Cancer Hospital and Research Institute

11:45 15 Phase I Trial of Antisense Oligo Against Vascular Endothelial Growth Factor (VEGF-AS, Veglin) in Relapsed and Refractory Malignancies
Alexandra M. Levine, M.D., Distinguished Professor of Medicine, Chief of Hematology, and Ronald H. Bloom Family Chair in Lymphoma, USC School of Medicine and Medical Director, Norris Cancer Hospital and Research Institute

Noon Lunch

1:00 - 1:45 PM Viral Load Assays: Utility and Issues
Moderator: Richard F. Ambinder, M.D., Ph.D., Director, Division of Hematologic Malignancies, JHU School of Medicine

1:00 S18 Altered EBV Viral Setpoint Due to HIV-Related Immune Activation
Debbie van Baarle, Ph.D., Sanquin Blood Supply Foundation, The Netherlands

1:15 S19 Real Time Quantitative PCR Assays for Accurately Measuring Viral Load of HTLV, KSHV, EBV, HIV, HCV AND HBV: Uses and Potential Pitfalls
Denise Whitby, Ph.D., Head of Viral Epidemiology Section, AIDS Vaccine Program, NCI, NIH

1:30 S20 EBV AND KSHV Copy Number in Hodgkin’s Lymphoma and AIDS Lymphoma
Richard F. Ambinder, M.D., Ph.D., Director, Division of Hematologic Malignancies, JHU School of Medicine

1:45 - Abstract Presentations
Moderator: Robert Yarchoan, M.D., Branch Chief, HIV & AIDS Malignancy Branch, CCR, NCI, NIH

1:45 16 Flare of AIDS-associated KS Following HAART: A Manifestation of Immune Reconstitution Syndrome
David Aboulafia, M.D., Clinical Professor, University of Washington School of Medicine

2:00 17 Associations of Classic KS with Haplotypes of IL8, IL8RB, and IL13
Elizabeth E. Brown, M.P.H., Ph.D., Cancer Research Postdoctoral Fellow, NCI, NIH
2:15  18  KSHV Induced Angiogenesis and Differentiation to Lymphatic Endothelium
       Michael Lagunoff, Ph.D., Assistant Professor of Microbiology, University of Washington

2:30 PM  Break

3:00 -  Pathogenesis and Viral Oncology Session
4:00 PM  Moderator: Patrick Moore, M.D., M.P.H., Director, Molecular Virology Program, University of
          Pittsburgh Cancer Institute and Hillman Cancer Center

3:00  S21  Rethinking the Pathogenesis of KS
         Donald E. Ganem, M.D., Professor of Microbiology and Immunology, UCSF

3:20  S22  The Latency-associated Nuclear Antigen of KSHV Modulates Cellular Gene Expression and
         Protects Lymphoid Cells From p16ink4a-induced Cell Cycle Arrest
         Rolf Renne, Ph.D., Assistant Professor of Molecular Biology and Microbiology, Case Western
         Reserve University

3:40  S23  Tumorigenic Mechanisms of KSHV
         Ashlee Moses, Ph.D., Assistant Scientist, Vaccine and Gene Therapy Institute, OHSU

4:00 -  Abstract Presentations
5:00 PM  Moderator: Denise Whitby, Head of Viral Epidemiology Section, AIDS Vaccine Program, NCI, NIH

4:00  19  KSHV and RRV Capsid Structure at ≤10 Å Resolution and Identification of RRV- associated
         Proteins by Tandem Mass Spectrometry
         Christine M. O’Connor, B.S., Graduate Student, University of Virginia

4:15  20  LANA Mediated Intranuclear Shuttling of KSHV Genomes
         Magdalena Weidner, B.S., Graduate Student, Kimmel Comprehensive Cancer Center, JHU

4:30  21  KSHV/HHV-8 Replication and Transcription Activator Regulated Both Viral and Cellular Genes
         by Binding to Interferon-Stimulated Response Element
         Luwen Zhang, Ph.D., Assistant Professor of Virology, University of Nebraska

4:45  22  A Second Self-reinforcing Loop Involving JUN/FOS, RTA, and RAP Drives KSHV Lytic Cycle
         Reactivation in PEL Cells at Earlier Stages than the C/EBPα, RTA, and RAP Loop
         Gary Hayward, M.D., Professor of Oncology, Pathology, Pharmacology, and Molecular Sciences,
         JHU School of Medicine

5:00 PM  Adjourn to posters

Continuing Medical Education
The National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) is accredited by
the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The NIH/FAES designates this education activity for a maximum of 13 hours in category 1 credit toward the AMA
Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in
the activity. The CME form is available at the registration desk outside the main auditorium.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute